MGNX Fundamental Analysis - MACROGENICS INC

Name: MACROGENICS INC (MGNX) Stock
Brand: MACROGENICS INC
Rating: 3.5 (3 reviews)

Fundamental Rating

MGNX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. The financial health of MGNX is average, but there are quite some concerns on its profitability. MGNX is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MGNX has reported negative net income.

MGNX had a negative operating cash flow in the past year.

MGNX had negative earnings in each of the past 5 years.

MGNX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

MGNX has a better Return On Assets (-14.83%) than 81.46% of its industry peers.

The Return On Equity of MGNX (-78.08%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-14.83%
ROE	-78.08%
ROIC	N/A

ROA(3y)-23.78%

ROA(5y)-33.18%

ROE(3y)-49.33%

ROE(5y)-55.24%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of MGNX (86.91%) is better than 88.76% of its industry peers.

MGNX's Gross Margin has declined in the last couple of years.

MGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	86.91%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.7%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, MGNX has more shares outstanding

The number of shares outstanding for MGNX has been increased compared to 5 years ago.

MGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

MGNX has an Altman-Z score of -6.42. This is a bad value and indicates that MGNX is not financially healthy and even has some risk of bankruptcy.

MGNX's Altman-Z score of -6.42 is on the low side compared to the rest of the industry. MGNX is outperformed by 65.54% of its industry peers.

MGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-6.42

ROIC/WACCN/A

WACC8.75%

2.3 Liquidity

MGNX has a Current Ratio of 5.25. This indicates that MGNX is financially healthy and has no problem in meeting its short term obligations.

MGNX has a Current ratio of 5.25. This is comparable to the rest of the industry: MGNX outperforms 57.49% of its industry peers.

A Quick Ratio of 5.02 indicates that MGNX has no problem at all paying its short term obligations.

MGNX has a Quick ratio of 5.02. This is comparable to the rest of the industry: MGNX outperforms 57.12% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.26
Quick Ratio	5.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 74.09% over the past year.

Looking at the last year, MGNX shows a very strong growth in Revenue. The Revenue has grown by 303.44%.

The Revenue has been growing by 18.49% on average over the past years. This is quite good.

EPS 1Y (TTM)74.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%35.96%

Revenue 1Y (TTM)303.44%

Revenue growth 3Y24.67%

Revenue growth 5Y18.49%

Sales Q2Q%107.88%

3.2 Future

Based on estimates for the next years, MGNX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.06% on average per year.

Based on estimates for the next years, MGNX will show a decrease in Revenue. The Revenue will decrease by -2.48% on average per year.

EPS Next Y-88.32%

EPS Next 2Y-23.91%

EPS Next 3Y-23.75%

EPS Next 5Y17.06%

Revenue Next Year-57.15%

Revenue Next 2Y-47.8%

Revenue Next 3Y-40.82%

Revenue Next 5Y-2.48%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MGNX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as MGNX's earnings are expected to decrease with -23.75% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-23.91%

EPS Next 3Y-23.75%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MGNX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MACROGENICS INC

NASDAQ:MGNX (11/7/2025, 8:00:01 PM)

After market: 1.39 +0.02 (+1.46%)

1.37

+0.01 (+0.74%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-14 2025-08-14/amc

Earnings (Next)11-11 2025-11-11

Inst Owners71.61%

Inst Owner Change0.4%

Ins Owners1.08%

Ins Owner Change1.82%

Market Cap86.60M

Revenue(TTM)165.49M

Net Income(TTM)-36.40M

Analysts75.38

Price Target3.47 (153.28%)

Short Float %6.14%

Short Ratio4.36

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)13.29%

Min EPS beat(2)8.09%

Max EPS beat(2)18.49%

EPS beat(4)4

Avg EPS beat(4)96.65%

Min EPS beat(4)8.09%

Max EPS beat(4)316.2%

EPS beat(8)5

Avg EPS beat(8)39.88%

EPS beat(12)6

Avg EPS beat(12)13.04%

EPS beat(16)7

Avg EPS beat(16)8.15%

Revenue beat(2)2

Avg Revenue beat(2)146.46%

Min Revenue beat(2)109.73%

Max Revenue beat(2)183.18%

Revenue beat(4)3

Avg Revenue beat(4)73.34%

Min Revenue beat(4)-42.16%

Max Revenue beat(4)183.18%

Revenue beat(8)3

Avg Revenue beat(8)7.2%

Revenue beat(12)5

Avg Revenue beat(12)-2.38%

Revenue beat(16)6

Avg Revenue beat(16)-5.19%

PT rev (1m)0%

PT rev (3m)-19.05%

EPS NQ rev (1m)0%

EPS NQ rev (3m)8.58%

EPS NY rev (1m)0%

EPS NY rev (3m)9.79%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)28.55%

Revenue NY rev (1m)0%

Revenue NY rev (3m)90.81%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.52
P/FCF	N/A
P/OCF	N/A
P/B	1.86
P/tB	1.86
EV/EBITDA	N/A

EPS(TTM)-0.57

EYN/A

EPS(NY)-1.66

Fwd EYN/A

FCF(TTM)-1.18

FCFYN/A

OCF(TTM)-1.14

OCFYN/A

SpS2.62

BVpS0.74

TBVpS0.74

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-14.83%
ROE	-78.08%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	86.91%
FCFM	N/A

ROA(3y)-23.78%

ROA(5y)-33.18%

ROE(3y)-49.33%

ROE(5y)-55.24%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.7%

GM growth 5YN/A

F-Score6

Asset Turnover0.67

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	32.46%
Cap/Sales	1.48%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.26
Quick Ratio	5.02
Altman-Z	-6.42

F-Score6

WACC8.75%

ROIC/WACCN/A

Cap/Depr(3y)32.65%

Cap/Depr(5y)40.48%

Cap/Sales(3y)2.62%

Cap/Sales(5y)4.3%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)74.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%35.96%

EPS Next Y-88.32%

EPS Next 2Y-23.91%

EPS Next 3Y-23.75%

EPS Next 5Y17.06%

Revenue 1Y (TTM)303.44%

Revenue growth 3Y24.67%

Revenue growth 5Y18.49%

Sales Q2Q%107.88%

Revenue Next Year-57.15%

Revenue Next 2Y-47.8%

Revenue Next 3Y-40.82%

Revenue Next 5Y-2.48%

EBIT growth 1Y60.35%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-14.54%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-2475.03%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-1548.19%

OCF growth 3YN/A

OCF growth 5YN/A

MACROGENICS INC / MGNX FAQ

Can you provide the ChartMill fundamental rating for MACROGENICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to MGNX.

What is the valuation status for MGNX stock?

ChartMill assigns a valuation rating of 0 / 10 to MACROGENICS INC (MGNX). This can be considered as Overvalued.

What is the profitability of MGNX stock?

MACROGENICS INC (MGNX) has a profitability rating of 2 / 10.

MACROGENICS INC (MGNX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MACROGENICS INC / MGNX FAQ

Can you provide the ChartMill fundamental rating for MACROGENICS INC?

What is the valuation status for MGNX stock?

What is the profitability of MGNX stock?